Prediction of Cognitive Decline in Healthy Aging Based on Neuropsychiatric Symptoms and PET-biomarkers of Alzheimer's Disease

Overview

Journal J Neurol

Specialty Neurology

Date 2023 Dec 20

PMID 38114820

Authors

Lucas Ronat

Alexandru Hanganu

Daphne Chylinski

Maxime Van Egroo

Justinas Narbutas

Gabriel Besson

Vincenzo Muto

Christina Schmidt

Mohamed Ali Bahri

Christophe Phillips

Eric Salmon

Pierre Maquet

Gilles Vandewalle

Fabienne Collette

Christine Bastin

Affiliations

Soon will be listed here.

Abstract

Neuropsychiatric symptoms (NPS) have been associated with a risk of accelerated cognitive decline or conversion to dementia of the Alzheimer's Disease (AD) type. Moreover, the NPS were also associated with higher AD biomarkers (brain tau and amyloid burden) even in non-demented patients. But the effect of the relationship between NPS and biomarkers on cognitive decline has not yet been studied. This work aims to assess the relationship between longitudinal cognitive changes and NPS, specifically depression and anxiety, in association with AD biomarkers in healthy middle-aged to older participants. The cohort consisted of 101 healthy participants aged 50-70 years, 66 of whom had neuropsychological assessments of memory, executive functions, and global cognition at a 2-year follow-up. At baseline, NPS were assessed using the Beck Depression and Anxiety Inventories while brain tau and amyloid loads were measured using positron emission topography. For tau burden, THK5351 uptake is used as a proxy of tau and neuroinflammation. Participants, declining or remaining stable at follow-up, were categorized into groups for each cognitive domain. Group classification was investigated using binary logistic regressions based on combined AD biomarkers and the two NPS. The results showed that an association between anxiety and prefrontal amyloid burden significantly classified episodic memory decline, while the classification of global cognitive decline involved temporal and occipital amyloid burden but not NPS. Moreover, depression together with prefrontal and hippocampal tau burden were associated with a decline in memory. The classification of participants based on executive decline was related to depression and mainly prefrontal tau burden. These findings suggest that the combination of NPS and brain biomarkers of AD predicts the occurrence of cognitive decline in aging.

Citing Articles

Classification of Parkinson's disease with and without dopaminergic deficiency based on non-motor symptoms and structural neuroimaging.

Ronat L, Rainville P, Monchi O, Hanganu A Neurol Sci. 2025; .

PMID: 39969749 DOI: 10.1007/s10072-025-08045-6.

References

Geda Y, Roberts R, Knopman D, Petersen R, Christianson T, Pankratz V . Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008; 65(10):1193-8. PMC: 2575648. DOI: 10.1001/archpsyc.65.10.1193. View

Mortby M, Ismail Z, Anstey K . Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults. Int Psychogeriatr. 2017; 30(2):221-232. DOI: 10.1017/S1041610217001909. View

Geda Y, Smith G, Knopman D, Boeve B, Tangalos E, Ivnik R . De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int Psychogeriatr. 2004; 16(1):51-60. DOI: 10.1017/s1041610204000067. View

Rosenberg P, Mielke M, Appleby B, Oh E, Geda Y, Lyketsos C . The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013; 21(7):685-95. PMC: 3428504. DOI: 10.1016/j.jagp.2013.01.006. View

Burhanullah M, Tschanz J, Peters M, Leoutsakos J, Matyi J, Lyketsos C . Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study. Am J Geriatr Psychiatry. 2019; 28(1):64-71. PMC: 6874723. DOI: 10.1016/j.jagp.2019.03.023. View

Krell-Roesch J, Syrjanen J, Machulda M, Christianson T, Kremers W, Mielke M . Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. Int J Geriatr Psychiatry. 2021; 36(9):1362-1369. PMC: 8451750. DOI: 10.1002/gps.5528. View

Panza F, Lozupone M, Bellomo A, Imbimbo B . Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?. Ageing Res Rev. 2019; 55:100948. DOI: 10.1016/j.arr.2019.100948. View

Mori T, Shimada H, Shinotoh H, Hirano S, Eguchi Y, Yamada M . Apathy correlates with prefrontal amyloid β deposition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2013; 85(4):449-55. DOI: 10.1136/jnnp-2013-306110. View

Bensamoun D, Guignard R, Furst A, Derreumaux A, Manera V, Darcourt J . Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People. J Alzheimers Dis. 2015; 49(2):387-98. DOI: 10.3233/JAD-150181. View

10.

Krell-Roesch J, Lowe V, Neureiter J, Pink A, Roberts R, Mielke M . Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. Int Psychogeriatr. 2017; 30(2):245-251. PMC: 5815897. DOI: 10.1017/S1041610217002368. View

11.

Brendel M, Pogarell O, Xiong G, Delker A, Bartenstein P, Rominger A . Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. Eur J Nucl Med Mol Imaging. 2015; 42(5):716-24. PMC: 5849231. DOI: 10.1007/s00259-014-2975-4. View

12.

Johansson M, Stomrud E, Lindberg O, Westman E, Johansson P, van Westen D . Apathy and anxiety are early markers of Alzheimer's disease. Neurobiol Aging. 2019; 85:74-82. DOI: 10.1016/j.neurobiolaging.2019.10.008. View

13.

Yasuno F, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A . High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. Int J Geriatr Psychiatry. 2016; 31(8):920-8. DOI: 10.1002/gps.4409. View

14.

Ismail Z, Aguera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer C . The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. J Alzheimers Dis. 2017; 56(3):929-938. PMC: 5652315. DOI: 10.3233/JAD-160979. View

15.

Tommasi N, Gonzalez C, Briggs D, Properzi M, Gatchel J, Marshall G . Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease. Int J Geriatr Psychiatry. 2021; 36(7):1050-1058. PMC: 8187284. DOI: 10.1002/gps.5530. View

16.

Yasuno F, Minami H, Hattori H . Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study. Int J Geriatr Psychiatry. 2020; 36(4):598-605. PMC: 7933053. DOI: 10.1002/gps.5459. View

17.

Jack Jr C, Knopman D, Jagust W, Petersen R, Weiner M, Aisen P . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-16. PMC: 3622225. DOI: 10.1016/S1474-4422(12)70291-0. View

18.

Rizzolo L, Narbutas J, Van Egroo M, Chylinski D, Besson G, Baillet M . Relationship between brain AD biomarkers and episodic memory performance in healthy aging. Brain Cogn. 2021; 148:105680. DOI: 10.1016/j.bandc.2020.105680. View

19.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

20.

Beck A, Epstein N, Brown G, Steer R . An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56(6):893-7. DOI: 10.1037//0022-006x.56.6.893. View